SEC Form 4 · accession 0001179110-15-011308
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William K Heiden
Officer — CEO · Director
Period of report
Jul 15, 2015
Accepted (ET)
Jul 17, 2015 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2015 | M | 20,000 | $12.99 | A | 226,721 | D | |
| Common Stock | Jul 15, 2015 | S | 20,000 | $75.00 | D | 206,721 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $12.99 | Jul 15, 2015 | M | 20,000 | D | — | May 14, 2022 | Common Stock | 20,000 | 210,000 | D |
Explanation of responses
- F1The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2015.
- F2This option vests and becomes exercisable in four equal annual installments beginning May 14, 2013.